Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Standard co-folding models struggle with induced proximity because public databases like the PDB lack sufficient training data for multi-protein complexes. Because dynamic multi-protein complexes take on endless conformations, standard AI models become overconfident and inaccurate. To solve this, Protai generates proprietary structural proteomics data that maps physical distances and conformations, enabling accurate modeling of complexes that can be targeted by molecular glues and PROTACs.
Related Insights
To evolve AI from pattern matching to understanding physics for protein engineering, structural data is insufficient. Models need physical parameters like Gibbs free energy (delta-G), obtainable from affinity measurements, to become truly predictive and transformative for therapeutic development.
Models like AlphaFold don't solve protein folding from physics alone. They heavily rely on co-evolutionary data, where correlated mutations across species provide strong hints about which amino acids are physically close. This dramatically constrains the search space for the final structure.
The public database of protein structures (PDB) is small and grows slowly. To train more powerful models, Genesis leverages physics simulations to model small molecule behavior, creating a large, high-quality synthetic dataset that isn't possible for more complex protein-protein interactions.
Contrary to trends in other AI fields, structural biology problems are not yet dominated by simple, scaled-up transformers. Specialized architectures that bake in physical priors, like equivariance, still yield vastly superior performance, as the domain's complexity requires strong inductive biases.
Current AI for protein engineering relies on small public datasets like the PDB (~10,000 structures), causing models to "hallucinate" or default to known examples. This data bottleneck, orders of magnitude smaller than data used for LLMs, hinders the development of novel therapeutics.
Traditional methods like crystallography are slow and analyze purified proteins outside their native environment. A-muto's platform uses proteomics and AI to analyze thousands of protein conformations in living disease models, capturing a more accurate picture of disease biology and identifying novel targets.
ProPhet's strategy is to focus on 'hard-to-drug' proteins, which are often avoided because they lack the structural data required for traditional discovery. Because ProPhet's AI model needs very little protein information to predict interactions, this data scarcity becomes a competitive advantage.
AlphaFold 2 was a breakthrough for predicting single protein structures. However, this success highlighted the much larger, unsolved challenges of modeling protein interactions, their dynamic movements, and the actual folding process, which are critical for understanding disease and drug discovery.
The pipeline's high success rate stems from its final filter, which uses an AlphaFold model trained only on single proteins (monomers) to predict a protein complex. The rationale is that if a model naive to complexes can still predict the interaction, the interface must be exceptionally strong and well-defined.
Generative AI alone designs proteins that look correct on paper but often fail in the lab. DenovAI adds a physics layer to simulate molecular dynamics—the "jiggling and wiggling"—which weeds out false positives by modeling how proteins actually interact in the real world.
